Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Revenue recognized from beginning contract liability by Year
Revenue recognized from beginning contract liability balance ($M) ($M)
Vertex Pharmaceuticals Revenue recognized from beginning contract liability: $207M in FY2025, up 21.4% from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Revenue Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Revenue recognized from beginning contract liability balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 207 | +21.4% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 170 | +6.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 160 | -7.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 172 | -10.3% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 192 | +207.4% | Form 10-K (filed 2024-02-15) ↗ |
| FY2020 | Dec 31, 2020 | 62.3 | +150.2% | Form 10-K (filed 2023-02-10) ↗ |
| FY2019 | Dec 31, 2019 | 24.9 | +1,364.7% | Form 10-K (filed 2022-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 1.70 | – | Form 10-K (filed 2021-02-11) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Revenue recognized from beginning contract liability ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/contract-liab-rev-rec
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.